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Abstract
 
The chemokines are a homologous serum protein family
characterized by their ability to induce activation of integrin
adhesion molecules and leukocyte migration. Chemokines
interact with their receptors, which are composed of a sin-
gle-chain, seven-helix, membrane-spanning protein coupled
to G proteins. Two CC chemokine receptors, CCR3 and
CCR5, as well as the CXCR4 chemokine receptor, have
been shown necessary for infection by several HIV-1 virus
isolates.
We studied the effect of the chemokine monocyte chemo-
attractant protein 1 (MCP-1) and of a panel of MCP-1 re-
ceptor (CCR2)-specific monoclonal antibodies (mAb) on the
suppression of HIV-1 replication in peripheral blood mono-
nuclear cells. We have compelling evidence that MCP-1 has
potent HIV-1 suppressive activity when HIV-1–infected pe-
ripheral blood lymphocytes are used as target cells. Further-
more, mAb specific for the MCP-1R CCR2 which recognize
the third extracellular CCR2 domain inhibit all MCP-1 ac-
tivity and also block MCP-1 suppressive activity. Finally, a
set of mAb specific for the CCR2 amino-terminal domain,
one of which mimics MCP-1 activity, has a potent suppres-
sive effect on HIV-1 replication in M- and T-tropic HIV-1
viral isolates.
We conjecture a role for CCR2 as a coreceptor for HIV-1
infection and map the HIV-1 binding site to the amino-ter-
minal part of this receptor. This concurs with results show-
ing that the CCR5 amino terminus is relevant in HIV-1 in-
fection, although chimeric fusion of various extracellular
domains shows that other domains are also implicated. We
discuss the importance of CCR2 structure relative to its
coreceptor role and the role of anti-CCR2 receptor antibod-
 
ies in the prevention of HIV-1 infection. (
 
J. Clin. Invest.
 
1997. 100:497–502.) Key words: chemokine receptor 
 
• 
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• 
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Introduction
 
Chemokines are a family of proinflammatory cytokines which
attract and activate specific types of leukocytes. Based on the
position of the first two of four canonical cysteine residues and
the chromosomal location of the corresponding genes, two
main chemokine families, CC or 
 
a
 
 and CXC or 
 
b
 
, have been
identified. They act on monocytes, lymphocytes (including nat-
ural killer cells), basophils, eosinophils, and neutrophils (1–3).
Chemokines mediate their effects via interactions with a seven-
transmembrane glycoprotein receptor coupled to a G-protein
signaling pathway (4, 5). This type of receptor consists of a sin-
gle polypeptide chain with an extracellular amino-terminal do-
main and a cytoplasmic carboxy-terminal domain. The amino-
terminal and third extracellular domain have been implicated
in receptor–ligand interaction, while the carboxy-terminal and
the third intracellular domain cooperate to bind and activate
the G proteins (5).
The recent descriptions of the CCR3, CCR5 (6–12), and
CXCR4 or fusin (10, 13–15) chemokine receptors as HIV-1
coreceptors, and of the chemokine ligands RANTES, macro-
phage inflammatory protein-1
 
a
 
 (MIP-1
 
a
 
),
 
1
 
 and MIP-1
 
b
 
 as
neutralizing agents for HIV-1 infection, assign these molecules
a key role in HIV-1 pathogenesis (6–15). Monocyte chemoat-
tractant protein 1 (MCP-1), a CC chemokine family member,
is produced by endothelial cells, smooth muscle, and macro-
phages in response to a variety of stimuli (16). It has been im-
plicated as a mediator of monocyte and macrophage infiltra-
tion of tumor cells, where it may contribute to tumor growth
suppression (17). MCP-1 interacts with the CCR2 receptor and
induces histamine release, calcium influx, regulates integrin
expression, and acts as a chemotactic factor for monocytes/
macrophages, T cells, natural killer cells, basophils, mast cells,
and dendritic cells (18–20). We have assayed the ability of the
CCR2 receptor to act as an HIV-1 coreceptor on human
PBMC by testing the HIV-1 suppressive activity of MCP-1, as
well as the ability of monoclonal anti-CCR2 antibodies to in-
terfere with HIV-1 replication. Our studies show the impor-
tance of the CCR2 amino terminus as the domain interacting
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with HIV-1, and complement those analyses performed with
chimeras containing human CCR5 and CCR2B domains.
 
Methods
 
Flow cytometry analysis.
 
CCR2B-transfected Jurkat cells and mock-
transfected controls were centrifuged, plated in V-bottom 96-well
plates (2.5 
 
3
 
 10
 
5
 
 cells/well) and incubated with 5 
 
m
 
l/well of biotin-
labeled MCP-1R02 or MCP-1R05 mAb (in PBS containing 2% BSA
and 2% FCS, staining PBS) for 30 min at 4
 
8
 
C. Cells were washed
twice in staining PBS, streptavidin-PE was added, incubated for 30 min
at 4
 
8
 
C, and cells again washed twice. Cell staining was determined in
a Profile XL cell sorter (Coulter Corp., Miami, FL).
 
Western blot.
 
CCR2B-transfected Jurkat cells and mock-trans-
fected controls were centrifuged and resuspended in 50 mM Tris,
50 mM NaCl, 5 mM DTT buffer containing a cocktail of protease in-
hibitors. Cells were subjected to three to five freeze–thaw cycles and
centrifuged at 500 
 
g
 
 for 2 min at 4
 
8
 
C. The supernatant was collected,
centrifuged at 15,000 
 
g
 
 for 15 min at 4
 
8
 
C, and the pellet resuspended
in PBS. Lysates were electrophoresed under reducing conditions on
12.5% (wt/vol) SDS-polyacrylamide gels according to Laemmli’s
method. Gels were transferred to nitrocellulose on a semi-dry blotter
(Bio-Rad, Hercules, CA) for 60 min at 250 mA in a 48 nM Tris base,
38 mM glycine, 20% methanol buffer containing 0.037% SDS. The
membrane was blocked with 10% nonfat dry milk in PBS, and mAb
MCP-1R05 (5 
 
m
 
g/ml in PBS), alone or preincubated with the indi-
cated peptides [CCR2(24–38) and (273–292), 100 
 
m
 
g/ml in PBS, 60 min
at room temperature], was added and incubated with agitation for
120 min at room temperature. A peroxidase-labeled goat anti–mouse
immunoglobulin antibody (ICN Biochemicals, Inc., Costa Mesa,
CA), 1/5,000 dilution, was added and the blot was developed using
ECL (Amersham, Little Chalfont, United Kingdom) following the
manufacturer’s instructions.
 
Reverse transcriptase-PCR (RT-PCR).
 
Poly(A)
 
1
 
 RNA from trans-
fected Jurkat cells and human PBMC was prepared using the Quick-
Prep mRNA purification Kit (Pharmacia Biotech AB, Uppsala,
Sweden), treated with RNase-free DNase (Boehringer-Mannheim,
Mannheim, Germany), and first-strand cDNA was prepared with
oligo-dT using the First-Strand cDNA Synthesis Kit (Pharmacia Bio-
tech AB). PCR was performed using 
 
Taq 
 
polymerase in a cycler
(9600; Perkin-Elmer Corp., Norwalk, CT).
The following 5
 
9
 
 and 3
 
9
 
 (5
 
9
 
//3
 
9
 
) primer pairs were used to amplify
the indicated fragments: CCR1: ATGGAAACTCCAAACACCA-
CAGAGGACTATG // AGGAAAGTGAAGGCTGCAGGTGTG-
GTGAGTG; CCR2: ATGCTGTCCACATCTCGTTC // TCTATC-
GATTGTCAGGAGGA; CCR3: GTGTCATCACCAGCATCGTC
// CAGATGGCCATAACGAGCAG; CCR4: CATGGTCAGTG-
GCTGTGTTC // TCACCGCCTTGTTCTTCTTC; CCR5: CCATA-
CAGTCAGTATCAATTC // CCAACCTGTTAGAGCTACTG; and
fusin: GTCCACGCCACCAACAGTC // CAGGCAAAGAAAGC-
TAGGATGAGGAT.
 
Monoclonal antibodies.
 
Murine mAb were raised against human
CCR2B by immunization with KLH-coupled synthetic peptides of
CCR2B receptor amino acids 24–38 and 273–292. Spleen and/or
lymph node cells were then fused with the P3X63Ag8.653 myeloma
line (CRL 1580; American Type Culture Collection, Rockville, MD)
using polyethylene glycol 4000 (Merck, Darmstadt, Germany). Anti-
body specificity was determined by enzyme immunoassay, immuno-
fluorescent cell sorting, immunoprecipitation, and Western blot in
cells transfected with the human CCR2 gene. Antibodies were puri-
fied and isotypes determined by enzyme immunoassay; the MCP-
1R02 and MCP-R105 antibodies are both IgG2a. Since the amino
acid sequence selected to produce these antibodies is shared by
CCR2A and CCR2B, the mAb should react equally with both recep-
tor forms.
 
Calcium determinations.
 
Changes in intracellular calcium concen-
tration were monitored using the fluorescent probe Fluo-3 (Calbio-
chem, San Diego, CA). MonoMac 1 cells (DSM ACC252; German
Microorganism and Cell Culture Collection, Braunschweig, Ger-
many) (2.5 
 
3
 
 10
 
6
 
 cells/ml) were suspended in RPMI 1640 containing
10 mM Hepes and incubated with 25 
 
m
 
l Fluo-3 (250 mM in DMSO,
15 min at 37
 
8
 
C). Cells were then washed and resuspended in com-
plete medium containing 2 mM CaCl
 
2
 
. To determine the activity of
antagonistic mAb, Fluo-3–loaded cells were incubated with various
concentrations of purified antibodies in RPMI (30 min at 4
 
8
 
C) before
MCP-1 stimulation (PeproTech Inc., London, United Kingdom). Cal-
cium release was then determined in the cell sorter at 525 nm. For ag-
onistic mAb, Fluo-3–loaded cells were stimulated with cytokines or
mAb, and Ca
 
2
 
1
 
 influx determined as above.
 
Chemotaxis.
 
MonoMac 1 cells were placed in the upper well of
24-well transmigration chambers (Transwell; Costar Corp., Cam-
bridge, MA) previously coated with mouse brain endothelial cells
(5 
 
3
 
 10
 
4
 
 cells/well, 48 h at 37
 
8
 
C, 5% CO
 
2
 
). Chemokines or agonist an-
tibody, diluted in RPMI containing 0.25% BSA, were added to the
lower well. Plates were incubated (120 min at 37
 
8
 
C, 5% CO
 
2
 
), the in-
serts were removed from the wells, and the cells which had migrated
to the lower chamber were counted. To block MCP-1–induced
chemotaxis, purified mAb diluted in PBS were added to the upper
well simultaneously with the addition of chemokines to the lower
well. Chemotaxis determination was as above.
 
Infectivity of PBL and HIV-1 p24 determination.
 
Human PB mono-
nuclear cells were activated with PHA (10 
 
m
 
g/ml, 48 h at 37
 
8
 
C, 5% CO
 
2
 
).
After washing, cells were incubated with NL4-3 viral stocks (2 ng/10
 
6
 
per assay, 37
 
8
 
C overnight). Cells were then washed extensively and
cultured in complete RPMI 1640 medium containing rhIL-2 (10 ng/ml)
with or without the chemokines MCP-1 or MIP-1
 
b
 
 and the antibodies
MCP-1R05 or hGH-14. Every 2 d after infection, half of the culture
supernatant (500 
 
m
 
l) was removed and replaced with fresh medium
containing IL-2, chemokines, and antibodies at their initial concen-
trations. Cell-free supernatants were tested for HIV-1 p24 antigen
content at d 2–8 after infection using a commercial ELISA test
(Coulter Corp.).
 
Results
 
CCR2B-specific antibodies block MCP-1–triggered cell activa-
tion.
 
We have generated a set of mAb to the human CCR2B
receptor, specific for either the amino-terminal (amino acids
24–38) or the third extracellular domain (amino acids 273–
292), illustrated here by mAb MCP-1R02 and MCP-1R05, re-
spectively. Antibody specificity was analyzed by immunopre-
cipitation, cytofluorometry, and Western blotting in Jurkat
cells, either mock-transfected or transfected with the CCR2B
gene. Wild-type Jurkat cells lack CCR2B receptor expression,
although they express the CCR4, CCR5, and fusin receptors,
as analyzed by RT-PCR (Fig. 1 
 
A
 
). Jurkat cells transfected
with a CCR2B receptor gene-bearing plasmid also express the
CCR2 receptor, as determined by RT-PCR (Fig. 1 
 
A
 
), fluores-
cence-activated cell sorting (Fig. 1 
 
B
 
), and Western blot analy-
ses (Fig. 1 
 
C
 
). In Western blot, the CCR2B receptor band is
abolished when these antibodies are incubated in the presence
of the peptides used for immunization (Fig. 1 
 
C
 
). In immuno-
fluorescence studies, both antibodies detect the CCR2B recep-
tor expressed in all human monocytes, as defined by anti-
CD14 antibodies. They also recognize the CCR2B receptor in
a significant fraction (40–70%) of activated peripheral blood–
or tonsil-derived human B cells, and in a minor population of
resting CD4
 
1
 
 T cells (not shown). These data concur with
those of Loetscher et al. (21) showing CCR2 expression in
PBMC preparations.
MCP-1 induces Ca
 
2
 
1
 
 influx in the monocyte cell line Mono-
Mac 1 and in human peripheral T cells (not shown). This Ca
 
2
 
1
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influx is blocked by the mAb specific for the third extracellular
domain of the CCR2B (MCP-1R05) (Fig. 2 
 
B
 
), as well as by
the two CCR2B receptor amino-terminal domain-specific anti-
bodies MCP-1R01 and MCP-1R02 (not shown), but not by an
irrelevant, isotype-matched mAb (Fig. 2 
 
A
 
). MCP-1R05 and
MCP-1R02 also block the MCP-1–triggered chemotactic re-
sponse in human monocytes in a concentration-dependent
fashion (not shown), as they do in MonoMac 1 cells (Fig. 2 
 
C
 
).
 
CCR2 acts a coreceptor for HIV-1 infection.
 
Three other CC
chemokine family members, RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
,
all of which interact with CCR5, display the HIV-1 suppressive
activity which has been implicated in infection control of this
virus (6–12). We demonstrate here that MCP-1 has suppres-
sive activity against the NL4-3 HIV-1 strain, which was derived
from NY5 (5
 
9
 
) and LAV (3
 
9
 
) isolated from PBMC (22, 23); it
replicates in peripheral blood lymphocytes and was cultured in
the Jurkat-derived CD4
 
1
 
 T cell line J-Jhan. Dose-dependent
inhibition of extracellular HIV-1 p24 antigen release was ob-
served for MIP-1
 
b
 
 and RANTES as described (6), but also for
MCP-1, with an end dilution (ED
 
95
 
) of 1–20 nM (Fig. 3). This
concurs with earlier results for MIP-1
 
b
 
, correlating the con-
centration range at which MCP-1 displays HIV-1 suppressive
activity with that required for biological responses (0.01–10 nM),
as analyzed by Ca
 
2
 
1
 
 influx, chemotactic responses, and T cell
signaling. We have excluded the possibility that this antiviral
activity is due to a negative effect on cellular proliferation, as
MCP-1 does not affect human peripheral blood T cell prolifer-
ative responses to PHA stimulation (not shown).
As shown, MCP-1R05 eliminates the MCP-1 suppressive
activity in a dose-dependent manner (Fig. 3), while it has little
or no effect on the HIV-1 suppressive activity of MIP-1
 
b
 
 and
RANTES (not shown). Isotype-matched antibodies of irrele-
vant specificity have no effect on extracellular p24 release after
HIV-1 infection of PBL (Fig. 3). The MCP-1R05 antibody
blocks virtually all HIV-1 suppressive activity promoted by
MCP-1. The blocking effect of MCP-1R05 is dose dependent
and, at the highest concentration used, no suppressive MCP-1
activity remains (Fig. 3). In fact, at 15 
 
m
 
g/ml, the p24 concen-
tration observed is at the same level as in the absence of MCP-1.
The specificity of MCP-1 inhibition by MCP-1R05 is in accor-
dance with results obtained in Ca
 
2
 
1
 
 influx and chemotactic re-
sponse inhibition studies.
In a second approach to the unraveling of CCR2 function,
we tested two mAb (MCP-1R01 and MCP-1R02) specific for
the amino-terminal part of this human chemokine receptor
(amino acids 24–38). This sequence was chosen for its possible
implication in ligand binding, based on data for other chemo-
kine receptors such as the IL-8R (24). In contrast to MCP-1R05,
the MCP-1R01 and MCP-1R02 antibodies display dose-depen-
dent HIV-1 suppressive activity, with an ED
 
95
 
 of 1–10 nM,
mimicking the activity of MCP-1 itself (Fig. 4 
 
A
 
). These results
clearly dissociate the chemokine ligand-binding domains of the
CCR2 receptor from those used by HIV-1 as a coreceptor.
MCP-1 suppressive activity was tested in other HIV-1 viral
strains; MCP-1, as well as MCP-1R02 and MCP-1R01, clearly
suppresses other M-tropic HIV-1 viral isolates such as BaL
(Fig. 4 
 
B
 
), but was ineffective with the T-tropic JC-CSF isolate
(not shown).
At least five different 
 
b
 
-chemokine receptors have been in-
volved in chemokine binding. Three of them, CCR3, CCR5,
and fusin, act as coreceptors for HIV-1 (6–12, 25), and the
presence of the appropriate chemokine prevents viral infec-
tion. Here we show compelling evidence that CCR2 also acts
as an HIV-1 coreceptor. Our data concur with the very recent
results obtained using the HIV-1 89.6 isolate, in which the
CCR2 receptor is implicated in syncytium formation (10).
MIP-1
 
b
 
 also suppresses NL4-3 replication, implying that this
HIV-1 isolate might also use CCR5 as coreceptor. If this is in-
deed the case, the suppression of NL4-3 replication by both
MCP-1 and MIP-1
 
b
 
 may be explained by cross-desensitization
of the two receptors used by the chemokines upon specific re-
ceptor binding (not shown).
Figure 1. The MCP-
1R02 and MCP-1R05 
antibodies are specific 
for the CCR2B chemo-
kine receptor. Amplifi-
cation of gene frag-
ments corresponding to 
the chemokine recep-
tors CCR1 (564 bp), 
CCR2 (417 bp), CCR3 
(205 bp), CCR4 (243 bp), 
CCR5 (280 bp), and 
fusin (338 bp) with spe-
cific primers (see Meth-
ods). (A) RT-PCR was 
performed with cDNA 
obtained from Jurkat 
cells transfected with pCDNA-3 (2), with pCDNA-3 encoding the 
CCR2B gene (1) and with human PBMC (C). CCR2B-transfected 
Jurkat cells (JK1) or mock-transfected controls (JK2) were incubated 
with the biotin-labeled antibodies MCP-1R02 and MCP-1R05, as in-
dicated, followed by streptavidin-PE (B). The figure shows mAb 
binding to JK1 cells compared with JK2. Western blot (C) analysis of 
JK1 cell lysates was performed, using mAb MCP-1R05 alone or pre-
incubated with the immunizing peptide, CCR2B (273–292), or with 
the amino-terminal receptor region peptide CCR2B (24–38), as indi-
cated.
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Discussion
 
Chemokines interact with their receptors in a complex, multi-
site manner (26, 27). The amino terminus and the third extra-
cellular domain of the receptor are thought to fold into prox-
imity on the intact receptor and join by a disulfide bridge (28).
Antibodies specific for the chemokine receptor fusin have
been shown to prevent cell fusion and infection of CD4
 
1
 
 T
cells with HIV-1 (13), but no further characterization of the
specificity of these antibodies was demonstrated. We now
present cogent data on the role of CCR2 as a coreceptor for
HIV-1. Using CCR2B-specific mAb, we have identified the
HIV-1 binding site on this coreceptor by showing that the re-
ceptor ligand-binding domain overlaps the HIV-1– and mAb-
binding domains, which do not themselves overlap. First,
MCP-1 which binds to CCR2B (19) shows HIV-1 suppressive
activity. Second, the MCP-1R05 antibody to the CCR2 recep-
tor third extracellular domain, and MCP-1R01 and MCP-R02
mAb to the amino terminus block MCP-1–triggered effects
such as Ca
 
2
 
1
 
 influx and chemotaxis, as well as the suppressive
effect of MCP-1 on HIV-1 replication. Third, the two anti–
amino-terminal antibodies, MCP-1R01 and MCP-1R02, but
not MCP-1R05, behave like MCP-1 and block HIV-1 virus in-
fection. The amino-terminal residues of the CCR2B receptor
appear to be necessary for HIV-1 binding; this contrasts with
the situation of the chemokines, which in addition require the
third extracellular domain. This difference might reflect the di-
verse nature of the ligands and may be used to advantage to
design therapeutic tools which prevent HIV-1 infection but
preserve chemokine responses. Similar results in studies using
cells transfected with chimeric constructs of the CCR5 recep-
tor have recently permitted mapping of the amino-terminal
domain of this receptor as implicated in the HIV-1 virus inter-
action (29, 30). Our data support earlier studies in indicating
the importance of the chemokine receptor amino terminus for
chemokine activity (29, 30). The use of CCR5 receptor chime-
ras shows that simple analysis of deletion mutants cannot elu-
cidate which receptor elements are significant in its role as an
HIV-1 coreceptor (29, 31). M-tropic HIV-1 envelope protein
fusion thus requires the amino-terminal domain or the first in-
tracellular domain of the CCR5 receptor or, alternatively, a
chimeric gene containing the CCR5 amino-terminal domain
Figure 2. Antibodies specific for the human CCR2B block MCP-1–triggered Ca21 influx and transmigration. Induction of Ca21 influx was pro-
moted by human MCP-1 in MonoMac 1 cells preloaded with Fluo-3 and incubated with purified hGH-14 (A), MCP-1R05, or MCP-1R02 (B) an-
tibodies before stimulation with MCP-1 (5 nM). Calcium influx was determined in cell sorting at 525 nm. The negative control mAb hGH-14, iso-
type-matched to MCP-1R05, is specific for human growth hormone (hGH). The figure depicts one of five experiments performed. Chemotaxis 
(C) was assessed in endothelial cell–coated porous cell culture inserts. MonoMac 1 cells were incubated with increasing concentrations of MCP-
1R05, MCP-1R02, or control hGH-14 antibody in the upper chamber, and MCP-1 (1 nM in culture medium) was added to the lower chamber. 
Cells that migrated to the lower well were counted and expressed as a migration index, calculated as the x-fold increase in migration observed 
over the negative control (Medium). Data represent the mean of triplicate determinations, with the SD indicated. One experiment of four is rep-
resented.
Figure 3. MCP-1 displays suppressive HIV-1 activity that is blocked 
by MCP-1 antagonist antibodies specific for the CCR2B receptor. 
Several concentrations of MCP-1 and MIP-1b were tested for HIV-1 
suppressive activity (0.01–10 nM). The concentration of MCP-1 
(filled bars) and MIP-1b (dotted bars) yielding maximal HIV-1 inhib-
itory activity on activated PB mononuclear cell cultures (1 nM) was 
selected, using untreated culture supernatants (NIL) as control. The 
suppressive activity of MCP-1 (1 nM) and of MIP-1b (1 nM) was 
blocked in the presence of the indicated concentrations of the
MCP-1R05 or the MCP-1R01 antibody, using the hGH-14 antibody 
as control. The figure shows the results of one experiment of three 
performed.
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linked to the CCR2B receptor. Complementation studies such
as the one performed here might thus improve understanding
of how chemokine receptors can act as HIV-1 coreceptors, as
well as providing a biological basis for HIV-1 infection of
PBMC. In addition, these types of reagents may have thera-
peutic applications.
Except in a few cases addressing the in vivo biological rele-
vance of CCR5 (12, 25, 32, 33), most studies showing CCR3 or
CCR5’s coreceptor role in HIV infection were performed us-
ing the chemokine receptor expressed in transfected cell lines
(the human cervical carcinoma cell line HeLa; the murine em-
bryo fibroblast 3T3; Cos monkey kidney cells; the quail fibro-
sarcoma cell line QT6; and the Cf2th canine thymoma). In all
but one of these (7), in which CCR5 receptor–transfected Jur-
kat T cells were used, expression was transient. Furthermore,
system read-out in most of these experiments is by syncytium
formation, fusion reaction, or 
 
env
 
-mediated reaction between
transiently expressing CCR5 receptor cells and cells infected
with a recombinant vaccinia virus carrying the 
 
env
 
 glycopro-
tein. We used PBL as HIV-1 infection targets and measured
viral replication by determining the amount of p24 present in
cell cultures. In no other instance were PBL used as target
cells, except in the original paper by Cocchi et al. (6); interest-
ingly, these authors tested the MCP-1 effect using not PBL but
rather the PM1 cell line as target cells, and no effect was ob-
served. It is convenient to recall the misinterpretations in HIV
research based on the overuse of cell lines as targets for HIV-1
infection. In light of previous data showing that CCR5 is the
major coreceptor for M-tropic HIV-1 strains such as BaL, our
results can be interpreted in several ways. Inhibition of BaL
replication in CD4
 
1
 
 T cells by MCP-1 or the MCP-1R02 anti-
body might be achieved in two ways. First, and we believe
most likely, we have shown that during MCP-1–triggered acti-
vation and chemotaxis, leukocytes polarize in such a way that
chemokine receptors migrate toward the leading edge of the
cell (34). The polarization of chemokine receptors is quite
probably related to their subsequent endocytosis, and may
thus take part in preventing HIV-1 infection of the chemo-
kine-targeted cell. As a second possibility, when MCP-1 and
the agonist mAb MPC-1R02 interact with the CCR2 receptor,
they trigger macrophage and T cell activation; this is measured
by the products of soluble mediators, some of which may be
implicated in HIV-1 replication control. And third, the ability
of a virus to use a coreceptor molecule does not preordain that
the virus can use that molecule regardless of the cell type on
which it is expressed. Posttranslational modification of core-
ceptors, for instance, may dispose them to cell infection only
by certain HIV-1 strains. Circumspection has been advised
with reference to the results that chemokine coreceptors accu-
rately reflect the cellular tropism of the virus (35).
Given the lack of appropriate reagents, previous studies in-
deed required specific chemokine receptor expression. These
results therefore complement earlier work, as we have gener-
ated these reagents; we can now identify the role of these re-
ceptors in normal leukocytes. Using our anti-CCR2B mAb
panel, the ability of each mAb to recognize the transfected
CCR2B receptor was compared in several cell lines; surpris-
ingly, variation in the antibody reactivity pattern was detected.
The reason for this is not yet understood, but warns that cau-
tion is needed when receptors are expressed in different cell
lines and functional assays are used.
The mechanisms through which chemokines exert their in-
hibitory effects are complex, and may include receptor block-
ade, desensitization, sequestration, or internalization. Since the
Figure 4. MCP-1 agonist 
antibody specific for the 
human CCR2B shows 
HIV-1 suppressive activ-
ity. (A) The HIV-1 sup-
pressive activity of the 
MCP-1R02 mAb (j) was 
tested as described in the 
legend to Fig. 3, and com-
pared with that of the 
control hGH-30 mAb (d) 
and MCP-1R05 antago-
nist mAb (m) using the 
NL4-3 viral strain and 
PBL as target cells. (B) 
The suppressive activity 
of the MCP-1R02 mAb 
(200 pM) was also tested 
using the BaL viral strain. 
As positive controls, the 
suppressive activities of 
MCP-1 (1 nM) and
MIP-1b (1 nM) are 
shown. Data represent 
the means of triplicate 
determinations6SD. The 
figure shows one repre-
sentative experiment of 
three performed.
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antibody promoting HIV-1 suppressive activity also triggers
chemokine responses, HIV-1 may be inactivated through the
chemokine receptor–triggered signal transduction pathway, an
interconnected cascade of G proteins and cell-specific catalytic
enzymes which involves G protein activation, the MAPK cas-
cade, and the serine/threonine and tyrosine kinases (27). Fi-
nally, HIV-1 tropism may be a result of the differential expres-
sion of chemokine receptors on leukocytes. The T-tropic virus
thus usually fails to enter macrophages, while M-tropic viruses
generally do not enter transformed T cell lines. Since our anti-
bodies recognize the chemokine receptor on T cells as well as
on macrophages, they may inhibit both macrophage-tropic and
T cell–tropic HIV-1 virus and therefore be effective therapeu-
tic instruments for use against HIV-1 infection.
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